SubHero Banner

Opdivo® (nivolumab), Yervoy®(ipilimumab) – New indication

May 15, 2020 - Bristol Myers Squibb announced the FDA approval of Opdivo (nivolumab), as first-line treatment in combination with Yervoy (ipilimumab) in adult patients with metastatic non-small cell lung cancer (NSCLC) expressing PD-L1 (≥ 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Download PDF